Zwueste D, Vernau K, Vernau W, Pypendop B, Knych H, Rodrigues C
J Vet Intern Med. 2023; 37(6):2429-2442.
PMID: 37670479
PMC: 10658504.
DOI: 10.1111/jvim.16842.
Rudd S, Tsesmetzis N, Sanjiv K, Paulin C, Sandhow L, Kutzner J
EMBO Mol Med. 2020; 12(3):e10419.
PMID: 31950591
PMC: 7059017.
DOI: 10.15252/emmm.201910419.
Rein L, Rizzieri D
Ther Adv Hematol. 2014; 5(6):211-20.
PMID: 25469211
PMC: 4250268.
DOI: 10.1177/2040620714552615.
Reese N, Schiller G
Curr Hematol Malig Rep. 2013; 8(2):141-8.
PMID: 23666364
DOI: 10.1007/s11899-013-0156-3.
Ju J, Qi Z, Cai X, Cao P, Huang Y, Wang S
PLoS One. 2013; 7(12):e52536.
PMID: 23300702
PMC: 3531419.
DOI: 10.1371/journal.pone.0052536.
Preparation and characterization of stable pH-sensitive vesicles composed of α-tocopherol hemisuccinate.
Xu H, Deng Y, Wang K, Chen D
AAPS PharmSciTech. 2012; 13(4):1377-85.
PMID: 23054989
PMC: 3513435.
DOI: 10.1208/s12249-012-9863-7.
Time controlled release of arabinofuranosylcytosine (Ara-C) from agarose hydrogels using layer-by-layer assembly: an in vitro study.
Mehrotra S, Lynam D, Liu C, Shahriari D, Lee I, Tuszynski M
J Biomater Sci Polym Ed. 2011; 23(1-4):439-63.
PMID: 21294967
PMC: 3873741.
DOI: 10.1163/092050610X552221.
Clinical pharmacokinetics of cytarabine formulations.
Hamada A, Kawaguchi T, Nakano M
Clin Pharmacokinet. 2002; 41(10):705-18.
PMID: 12162758
DOI: 10.2165/00003088-200241100-00002.
Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.
Kinsella A, Smith D, Pickard M
Br J Cancer. 1997; 75(7):935-45.
PMID: 9083327
PMC: 2222738.
DOI: 10.1038/bjc.1997.164.
Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside.
CAPIZZI R
Invest New Drugs. 1996; 14(3):249-56.
PMID: 8958179
DOI: 10.1007/BF00194527.
Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
Horber D, Schott H, Schwendener R
Br J Cancer. 1995; 71(5):957-62.
PMID: 7734320
PMC: 2033768.
DOI: 10.1038/bjc.1995.185.
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study.
Fleming R, CAPIZZI R, Rosner G, Oliver L, Smith S, Schiffer C
Cancer Chemother Pharmacol. 1995; 36(5):425-30.
PMID: 7634384
DOI: 10.1007/BF00686192.
Heuristic modeling of drug delivery to malignant brain tumors.
Levin V, PATLAK C, Landahl H
J Pharmacokinet Biopharm. 1980; 8(3):257-96.
PMID: 7420270
DOI: 10.1007/BF01059646.
Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro.
Streifel J, Howell S
Proc Natl Acad Sci U S A. 1981; 78(8):5132-6.
PMID: 6975478
PMC: 320347.
DOI: 10.1073/pnas.78.8.5132.
Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.
Wiley J, Jones S, Sawyer W, Paterson A
J Clin Invest. 1982; 69(2):479-89.
PMID: 6948829
PMC: 370998.
DOI: 10.1172/jci110472.
Cytosine arabinoside triphosphate production in human leukaemic myeloblasts: interactions with deoxycytidine.
Harris A, Grahame-Smith D
Cancer Chemother Pharmacol. 1981; 5(3):185-92.
PMID: 6945922
DOI: 10.1007/BF00258478.
A phase I-II study of combination therapy with thymidine and cytosine arabinoside.
Fram R, Major P, Egan E, Beardsley P, Rosenthal D, Kufe D
Cancer Chemother Pharmacol. 1983; 11(1):43-7.
PMID: 6883625
DOI: 10.1007/BF00257416.
Dynamics of pyrimidine deoxynucleoside triphosphate pools in relationship to DNA synthesis in 3T6 mouse fibroblasts.
Nicander B, REICHARD P
Proc Natl Acad Sci U S A. 1983; 80(5):1347-51.
PMID: 6572394
PMC: 393594.
DOI: 10.1073/pnas.80.5.1347.
Antitumor cell and antimetabolic effects of 5-ethyl-2'-deoxyuridine and 5'-substituted 5-ethyl-2'-deoxyuridine derivatives.
Balzarini J, De Clercq E, Kiefer G, Keppeler K, Buchele A
Invest New Drugs. 1984; 2(1):35-47.
PMID: 6469497
DOI: 10.1007/BF00173785.
Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.
Ellims P
Cancer Chemother Pharmacol. 1982; 10(1):1-6.
PMID: 6186411
DOI: 10.1007/BF00257227.
